Schott Pharma announces pre-filled polymer syringes for deep-cold medication

James Spargo | May 19, 2023 | News story | Medical Communications Devices, Schott Pharma, deep cold medication, syringe 

Germany-based drug delivery solutions company Schott Pharma has announced its pre-fillable syringes (PFS) for drugs requiring deep-cold, such as those needing to be stored and transported at temperatures as low as -100ºC.

TOPPAC freeze is made with an advanced pharmaceutical-grade cyclic olefin copolymer (COC) which is break-resistant and biologically inert, enabling drug stability within the PFS. It is also compatible with major fill-and-finish lines, simplifying the filling process and enabling faster time-to-market.

Schott Pharma’s CEO Andreas Reisse said: “While PFSs are typically favoured for drug delivery due to their speed and convenience, they were not a viable option for drugs that require storage at -100°C. But now, for the first time, deep-cold medications can be introduced to the market using polymer PFSs. The drug development pipeline for these drugs is extensive, including various therapies such as mRNA and cell and gene therapies.”

Schott Pharma drug delivery systems business segment head, Mario Haas commented, “Our polymer syringes are a favourable choice for deep-cold drugs thanks to the entire platform system, which includes the polymer material, siliconisation, the plunger material and the overall quality management system, among others. Based on our track record in the field of mRNA-based applications, we are ready to bring the next deep-cold drugs to the market together with our customers. Furthermore, our state-of-the-art manufacturing process is designed to achieve consistently high quality. Combined with enhanced quality control of all critical to quality (CtQ) syringe attributes, we can ensure that each polymer syringe fulfils the high requirements needed for deep-cold applications.”

James Spargo

Related Content

No items found

Latest content